|
|
|
|
| LEADER |
00000cam a2200000 4500 |
| 001 |
ocn870245942 |
| 003 |
OCoLC |
| 005 |
20240809213013.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
140208s2013 sz o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d AU@
|d OCLCQ
|d REDDC
|d OCLCF
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|
| 020 |
|
|
|a 9789240691803
|
| 020 |
|
|
|a 9240691804
|
| 035 |
|
|
|a (OCoLC)870245942
|
| 050 |
|
4 |
|a RS189 .W47
|
| 049 |
|
|
|a HCDD
|
| 100 |
1 |
|
|a Organization, World Health.
|
| 245 |
1 |
0 |
|a WHO Drug Information Vol. 27 No. 2 2013.
|
| 260 |
|
|
|a Geneva :
|b World Health Organization,
|c 2013.
|
| 300 |
|
|
|a 1 online resource (117 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Cover; Contents; Quality and Safety of Medicines; WHO project for the surveillance and monitoring of SSFFC medical products; Surveillance and monitoring; Rapid Alert Form; SSFFC data base; Review and analysis; Final classification; Training workshop and pilot study; Challenges; Next Steps; Conclusion; Safety and Efficacy Issues; Azithromycin: potential risk of QT prolongation; Singapore; Osteoporosis treatments: atypical femur fracture; New Zealand; Ezogabine: retinal abnormalities and blue skin discoloration; United States of America.
|
| 505 |
8 |
|
|a Incretin mimetics: risk of pancreatitis and pancreatic duct metaplasiaUnited States of America; Incretin mimetics and GLP-1-based therapies: pancreatic risks; European Union; Belatacept: acute graft rejection Cinacalcet: fatal paediatric hypocalcaemia; United Kingdom; Cinacalcet: fatal paediatric hypocalcaemia; United Kingdom; Cilostazol-containing medicines: restricted use; European Union; Aqueous cream: skin irritation; United Kingdom; Zolpidem products: lower doses recommended; United States of America; Valproate-related products: risks during pregnancy; United States of America.
|
| 505 |
8 |
|
|a Thalidomide: risk of second primary malignanciesCanada; Botulinum toxin type B: serious risks; United Kingdom; Magnesium sulphate during pregnancy: teratogenic effects; United States of America; Varenicline and buproprion: revision to consumer information; Canada; Regulatory Action and News; Recommended influenza virus vaccine composition: 2013-2014 Northern hemisphere season; Wold Health Organization; Counterfeit antimalarial medicines: detection tool; United States of America; Black triangle for medicines subject to additional monitoring; European Union; Levothyroxine: licence suspension.
|
| 505 |
8 |
|
|a United KingdomStrontium ranelate: restricted use; European Union; Tetrazepam-containing medicines: suspension; European Union; Dabigatran etexilate: updated contraindications; European Union; Idebenone: voluntary withdrawal; Canada; Autologous chondrocyte implantation approved for cartilage defects; European Union; Vismodegib approved for basal cell carcinoma; European Union; Lenalidomide: approved for myelodysplastic syndromes; European Union; Nimodipine oral solution approved for subarachnoid haemorrhage; United States of America; Golimumab approved for ulcerative colitis.
|
| 505 |
8 |
|
|a United States of AmericaRadium dichloride approved for advanced prostate cancer; United States of America; Erlotinib and diagnostic test approved for non-small cell lung cancer; United States of America; Dabrafenib, trametinib and companion diagnostic test for advanced skin cancer; United States of America; Cysteamine bitartrate approved for rare genetic condition; United States of America; Fluticasone furoate and vilanterol approved for chronic obstructive pulmonary disease; United States of America; Oxycodone with abuse-deterrent properties approved; United States of America.
|
| 500 |
|
|
|a Imatinib approved for leukaemia.
|
| 520 |
|
|
|a WHO Drug Information communicates pharmaceutical information that is either developed and issued by WHO or transmitted to WHO by research and regulatory agencies throughout the World. The journal also includes regular presentations of newly proposed and recommended International Nonproprietary Names (INN) for Pharmaceuticals Substances. This volume contains the proposed INN List No. 109.
|
| 650 |
|
0 |
|a Drugs
|x Standards
|v Periodicals.
|
| 650 |
|
0 |
|a Pharmaceutical industry
|v Periodicals.
|
| 650 |
|
7 |
|a Drugs
|x Standards
|2 fast
|
| 650 |
|
7 |
|a Pharmaceutical industry
|2 fast
|
| 655 |
|
7 |
|a Periodicals
|2 fast
|
| 758 |
|
|
|i has work:
|a WHO Drug Information Vol. 27 No. 2 2013 (Text)
|1 https://id.oclc.org/worldcat/entity/E39PD3XFb9XCP6mMVjrWWpjkCP
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|a Organization, World Health.
|t WHO Drug Information Vol. 27 No. 2 2013.
|d Geneva : World Health Organization, ©2013
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/holycrosscollege-ebooks/detail.action?docID=1612002
|y Click for online access
|
| 903 |
|
|
|a EBC-AC
|
| 994 |
|
|
|a 92
|b HCD
|